Back to results
US 2024/0277794 A1Published application
Oncolytic viruses for modified mhc expression
AssigneeKaliVir Immunotherapeutics, Inc.
InventorsStephen Howard THORNE, Mingrui ZHANG
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for recombinant oncolytic viruses with gene deletions or insertions which result in downregulation of Major Histocompatibility Complex class I and alternatively or additively upregulation of Major Histocompatibility Complex class II. Immunologic and pharmaceutical compositions comprising these recombinant viruses and methods of using these compositions are also presented.
Claims28
A composition, wherein the composition comprises:
- an oncolytic virus, wherein the oncolytic virus comprises a genome modification,
- wherein the genome modification comprises an exogenous nucleic acid encoding for an MHC I inhibitor, wherein the MHC I inhibitor comprises dominant negative interferon regulator factor 7 (dnIRF7).
Dependencies are inferred from the claim text.